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Introduction: 
Currently different countries have to follow 
different regulatory requirements for approval 
of new drug. For marketing authorization 
application (MAA) a single regulatory 
approach is applicable to various countries is 
almost a difficult task. Therefore it is necessary 
to have knowledge about regulatory 
requirement for MAA of each country. The 
basic regulation can be understood from Fig 2. 
Drug approval in United States (1-3): 
The United States has perhaps the world’s most 
stringent standards for approving new drugs. 
Drug approval standards in the United States 
are considered by many to be the most 
demanding in the world. 
Investigational New Drug (IND) Application 
It’s an application filed to the FDA in order to 
start clinical trials in humans if the drug was 
found to be safe from the reports of Preclinical 
trials. A firm or institution, called a Sponsor, is 
responsible for submitting the IND application. 
A pre - IND meeting can be arranged with the 
FDA to discuss a number of issues: 
 The design of animal research, which is 
required to lend support to the clinical 
studies 
 The intended protocol for conducting 
the clinical Trial 
 The chemistry, manufacturing, and 
control of the investigational drug 
Such a meeting will help the Sponsor to 
organize animal research, gather data, and 
design the clinical protocol based on 
suggestions by the FDA. A clear flow chart of 
the IND process is illustrated in figure 1. 
New Drug Application (NDA) 
If clinical studies confirm that a new drug is 
relatively safe and effective, and will not pose 
unreasonable risks to patients, the manufacturer 
files a New Drug Application (NDA), the 
actual request to manufacture and sell the drug 
in the United States. The process of NDA has 
been illustrated in figure 3. 
Abbreviated New Drug Application (ANDA) 
It’s an application made for approval of 
Generic Drugs. The sponsor is not required to 
reproduce the clinical studies that were done 
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for the original, brand name product. Instead, 
generic drug manufacturers must demonstrate 
that their product is the same as, and 
bioequivalent to, a previously approved brand 
name product. The process of ANDA has been 
illustrated in figure 4. 
 
 
Figure 1: Flow chart of Investigational New Drug Application 
 
 
 
 
 
 
Figure 2: The Basic Regulation 
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      Figure 3: Flow chart of New Drug Application 
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     Figure 4: Flow chart of Abbreviated New Drug Application 
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Drug approval in Europe (4-6): 
Similar to the US requirements, there are two 
regulatory steps to go through before a drug is 
approved to be marketed in the European 
Union. These two steps are clinical trial 
application and marketing authorization 
application. There are 28 member states in the 
European Union (as of July, 2013); Clinical 
Trial Applications are approved at the member 
state level, whereas marketing authorization 
applications are approved at both the member 
state and centralized levels. 
Centralized procedure 
The centralized procedure is one which allows 
applicants to obtain a marketing authorization 
that is valid throughout the EU. 
 Results in a single authorization valid in 
EU, Norway, Iceland and Liechtenstein. 
 Application evaluated by an assigned 
Rapporteur. 
 Timeline: EMA opinion issued within 210 
days, and submitted to European 
Commission for final approval. 
Centralized process is compulsory for: 
 Those medicines which are derived from 
any biotechnology processes, such as 
genetic engineering. 
 Those medicines which are intended for 
the treatment of Cancer, HIV/AIDS, 
diabetes, neurodegenerative disorders or 
autoimmune diseases and other immune 
dysfunctions. 
 Medicines officially designated 'Orphan 
medicines' (medicines used for rare 
diseases).  
Mutual Recognition Procedure 
The Mutual Recognition procedure allows 
applicants to obtain a marketing authorization 
in the Concerned member states (CMS) other 
than the Reference member state (RMS), where 
the drug is previously approved. 
 Applicant submits identical dossier to all 
EU member states in which they want 
marketing authorization, including 
required information. 
 As soon as one Member State decides to 
evaluate the medicinal product (at which 
point it becomes the "RMS"), it notifies 
this decision to other Member States 
(which then become the "CMS"), to whom 
applications have also been submitted. 
 RMS issues a report to other states on its 
own findings. 
 Generic industry is the major user of this 
type of drug approval procedure. 
This process may consume a time period of 
390 days. 
Nationalized Procedure 
The Nationalized procedure is one which 
allows applicants to obtain a marketing 
authorization in one member state only. 
 In order to obtain a national marketing 
authorization, an application must be 
submitted to the competent authority of 
the Member State. 
 New active substances which are not 
mandatory under Centralized procedure 
can obtain marketing authorization under 
this procedure. 
 Timeline for this procedure is 210 Days. 
Decentralized procedure 
Using this procedure, companies may apply for 
authorization simultaneously in more than one 
EU country for products that have not yet been 
authorized in any EU country and essentially 
do not fall within the centralized procedure’s 
essential drugs list. 
Based on the assessment report which is 
prepared by the RMS & any comments made 
by the CMS, marketing authorization should be 
granted in accordance with the decision taken 
by the RMS & CMS in this decentralized 
procedure. 
 Generally used for those products that 
has not yet received any authorisation 
in an EU country. 
 Time: 210 days. 
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Figure 5: Flow chart of Centralized Procedure 
 
Figure 6: Flow chart of Mutual Recognition Procedure 
Approval of New Drug in India (7-10): 
When a company in India wants to 
manufacture/import a new drug it has to apply 
to seek permission from the licensing authority 
(DCGI) by filing in Form 44 also submitting 
the data as given in Schedule Y of Drugs and 
Cosmetics Act 1940 and Rules 1945. In order 
to prove its efficacy and safety in Indian 
population it has to conduct clinical trials in 
accordance with the guidelines specified in 
Schedule Y and submit the report of such 
clinical trials in specified format.  
But a provision is there in Rule - 122A of 
Drugs and Cosmetics Act 1940 and Rules 1945 
that the licensing authority may waive certain 
trails if he considers that in the interest of 
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public health he may grant permission for 
import of new drugs basing on the data of the 
trials done in other countries. Similarly there is 
another provision in Rule - 122A which says 
that the clinical trials may be waived in the 
case of new drugs which are approved and 
being used for several years in other countries. 
 
Figure 7: Flow chart of Decentralized Procedure 
 
Section 2.4 (a) of Schedule Y of Drugs and 
Cosmetics Act 1940 and Rules 1945 says for 
those drug substances which are discovered in 
India all phases of clinical trials are required.  
Section 2.4 (b) of Schedule Y of Drugs and 
Cosmetics Act 1940 and Rules 1945 says that 
for those drug substances which are discovered 
in countries other than India; the applicant 
should submit the data available from other 
countries and the licensing authority may 
require him to repeat all the studies or permit 
him to proceed from Phase III clinical trials.  
Section 2.8 of Schedule Y of Drugs and 
Cosmetics Act 1940 and Rules 1945 says that 
the licensing authority may require 
pharmacokinetic studies (Bioequivalence 
studies) first to show that the data generated in 
Indian population is equal to data generated 
abroad and then require him to proceed with 
Phase III trials.  
In summary, the exact requirements of Clinical 
trials may change from case to case and depend 
on the extent to which licensing authority is 
satisfied about its safety and efficacy. 
The process of approval of new drug in India is 
a very complicated process, which should meet 
necessary requirements along with NDA to 
FDA. The need of the present work is to study 
and document the requirements for the process 
of approval of new drug in India with emphasis 
on clinical trials as per Drugs Control 
department, Government of India.  
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New Drug Application 
NDA is an application submitted to the FDA 
for permission to market a new drug. To obtain 
this permission a sponsor submits preclinical 
and clinical test data to NDA for analyzing the 
drug information, description of manufacturing 
procedures.  
After NDA received by the agency, it 
undergoes a technical screening. This 
evaluation ensures that sufficient data and 
information have been submitted in each area 
to justify “filing” the application that is FDA 
formal review. At the conclusion of FDA 
review of an NDA, there are 3 possible actions 
that can send to sponsor:  
Not approvable- In this letter list of 
deficiencies and explain the reason.  
Approvable - It means that the drug can be 
approved but minor deficiencies that can be 
corrected like-labeling changes and possible 
request commitment to do post-approval 
studies.  
Approval- It state that the drug is approved.  
If the action taken is either an approvable or a 
not approvable, then FDA provides applicant 
with an opportunity to meet with agency and 
discuss the deficiencies. 
 
Drug approval process in India: 
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Results & Discussion: 
Table 1: Principle differences between US, EU & INDIA 
Requirements US EU INDIA 
Agency One Agency USFDA Multiple Agencies 
 EMEA 
 CHMP 
 National Health Agencies 
One Agency DCGI 
Registration 
Process 
One Registration 
Process 
Multiple Registration Process 
 Centralized (European 
Community) 
 Decentralized (At least 2 
member states) 
 Mutual Recognition (At 
least 2 member states) 
 National (1 member state) 
One Registration 
Process 
TSE/BSE Study 
data 
TSE/BSE Study data 
not required 
TSE/BSE Study data required TSE/BSE Study 
data required 
Braille code Braille code is not 
required on labelling 
Braille code is required on 
labelling 
Braille code is not 
required on 
labelling 
Post-approval 
changes 
Post-approval changes 
in the approved drug: 
 Minor changes 
 Moderate changes 
 Major changes 
Post-variation in the 
approved drug: 
 Type IA Variation 
 Type IB Variation 
 Type II Variation 
Post approval 
changes: 
Major quality 
changes 
Moderate quality 
changes 
 
Table 2: Administrative Requirements 
Requirements US EU INDIA 
Application ANDA / NDA MAA MAA 
Debarment 
classification 
Required Not Required Not Required 
Number of 
copies 
3 1 1 
Approval 
Timeline 
~18 Months ~12 Months 12 - 18 Months 
Fees Under $2 million-NDA 
Application 
$51,520 – ANDA 
Application 
National 
fee (including hybrid 
applications): 
£103,059  
Decentralised 
procedure where UK 
is CMS: £99,507 
50,000 INR 
Presentation eCTD & Paper eCTD Paper 
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Table 3: Finished Product Control Requirements 
Requirements US EU INDIA 
Justification ICH Q6A ICH Q6A ICH Q6A 
Assay 90 - 100 % 95 - 105 % 90 - 110 % 
Disintegration Not Required Required Required 
Colour 
Identification 
Not Required Required Required 
Water Content Required Not Required Required 
 
Table 4: Manufacturing & Control Requirements 
Requirements US EU INDIA 
Number of 
batches 
1 3 1 
Packaging A minimum of 1,00,000 
Units 
Not Required Not addressed 
Process 
Validation 
Not required at the time 
of submission 
Required Required 
Batch Size 1 pilot scale or 
minimum of 1 lakh units 
whichever is higher. 
2 pilot scale plus 1 lab batch or 
minimum of 1 lakh units 
whichever is higher. 
Pilot scale batch 
 
Table 5: Stability Requirements 
Requirements US EU INDIA 
Number of 
batches 
3 Pilot Batch or 2 Pilot 
Batch & 1 Small scale 
2 Pilot Scale (If API Stable) 
3 Primary Batches 
 (If API unstable) 
2 Pilot Scale/Production 
scale(If API Stable) 
3 Primary Batches (If API 
unstable) 
Condition: Long 
term  stability, 
Accelerated  
stability,  
Long term: 
25°C/60%RH 
Accelerated: 
40°C/75%RH(0,3,6 
months); Intermediate: 
30°C/65%RH  
Long term: 25°C/60%RH 
 Accelerated: 
40°C/75%RH(0,3,6 months) 
Intermediate: 30°C/65%RH  
Long term: 30°C/70%RH 
Accelerated:40°C/75%RH 
(0,3,6 months) 
Minimum time 
period at  
Submission 
6 Months Accelerate & 
6 Months long term 
6 Months Accelerate & 6 
Months long term 
6 Months Accelerate & 6 
Months long term 
Container 
orientation 
Inverted & Upright Do not address upright and inverted  
Clause 21 CFR part 210 & 211 Volume 4 EU Guidelines for 
medicinal products 
ICH Q1F 
QP Certification Not Required Required Required 
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Table 6: Bioequivalence Requirements 
Requirements US EU INDIA 
CRO 
(Audits) 
Audited by 
FDA 
Audited by 
MHRA 
CDSCO 
Reserve 
Sample 
5 times the sample 
required for analysis 
No such requirement - 
Fasted / Fed Must be as per OGD 
recommendation 
No such 
requirement 
As CDSCO 
recommendation 
Retention of 
samples 
5 years from date of 
filing the application 
No such requirement 3 years from date of filing 
the application 
BE study for 
generic drugs 
Against US RLD in any 
country. To refer ‘BE 
recommendations’ in 
FDA site for guidance. 
Against EU reference  
product (ERP) in any  
country 
Against US/EU/Australia 
RLD in any country except 
Thailand, where BE to be 
done locally against local 
reference product. 
 
Conclusion: 
The Drug approvals in the US, Europe & India 
are the most demanding in the world. The 
primary purpose of the rules governing 
medicinal products in US, Europe & India is to 
safeguard public health. It is the role of public 
regulatory authorities to ensure that 
pharmaceutical companies comply with 
regulations. There are legislations that require 
drugs to be developed, tested, trailed, and 
manufactured in accordance to the guidelines 
so that they are safe and patient’s well - being 
is protected. 
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